OverviewSuggest Edit
Zoetis is a company engaged in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products. It offers vaccines, anti-infectives, parasiticides, other pharmaceutical products, dermatology, medicated feed additives, and animal health diagnostics for cattle, swine, poultry, fish, and sheep as well as dogs, cats, and horses.
| Type | Public | |
| Founded | 2012 | |
| HQ | Parsippany-Troy Hills, NJ, US | Map |
| Website | zoetis.com | |
| Employee Ratings | More |
Recent NewsAll News
- Europe Companion Animal Diagnostics Market Set to Expand by 2020-2027 Focusing on Key Players Zoetis Inc, Randox Laboratories, Ltd., Idexx Laboratories, Inc., IDvet, Virbac
- Companion Animal Diagnostics Market examined in new market research report by top companies Skyla, Randox Laboratories, IDEXX Laboratories, Zoetis
- Animal Prescription Drugs Market SWOT Analysis by Key Players- Elanco Animal Health, Zoetis, Virbac, Dechra
- Consider Adding Zoetis, Garmin, And Intuit To Your Retirement Portfolio
Key People/Management at Zoetis
Kristin Peck
Chief Executive Officer and Director
Tim Bettington
Executive Vice President and President, U.S. Operations
Glenn David
Executive Vice President and Chief Financial Officer
Heidi Chen
Executive Vice President, General Counsel and Corporate Secretary
Rob Kelly
Executive Vice President and President, International Operations
Cathy Knupp
Executive Vice President and President, Research and Development
Zoetis Office Locations
Zoetis has offices in Parsippany-Troy Hills, DXS, Silverwater, Wien and in 46 other locations
Parsippany-Troy Hills, NJ, US (HQ)
10 Sylvan Way, Parsippany
DXS, AR
Virrey Loreto 2477
Wien, AT
Floridsdorfer Hauptstraße 1
Zaventem, BE
Mercuriusstraat 20
Sao Paulo, BR
Rua Luiz Fernando Rodrigues 1701
Kirkland, CA
16740 Route Transcanadienne
Zoetis Financials and Metrics
Zoetis Revenue
Zoetis's revenue was reported to be $6.26 b in FY, 2019 which is a 7.5% increase from the previous period.
| USD | |
|---|---|
Revenue (Q3, 2020) | 1.8b |
Gross profit (Q3, 2020) | 1.2b |
Gross profit margin (Q3, 2020), % | 69.4% |
Net income (Q3, 2020) | 479.0m |
Market capitalization (15-Jan-2021) | 76.8b |
Closing stock price (15-Jan-2021) | 161.6 |
Cash (30-Sept-2020) | 3.7b |
EV | 81.0b |
Zoetis's current market capitalization is $76.8 b.
Annual
Quarterly
Annual
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 350.0m | 732.0m | 1.1b | 312.0m | 683.0m | 1.1b | 423.0m | 799.0m | 1.3b |
Depreciation and Amortization | 60.0m | 123.0m | 207.0m | 98.0m | 196.0m | 303.0m | 110.0m | 221.0m | 332.0m |
Inventories | (33.0m) | (23.0m) | 29.0m | 17.0m | (50.0m) | (103.0m) | (97.0m) | (233.0m) | (294.0m) |
Accounts Payable | (46.0m) | (28.0m) | (39.0m) | (79.0m) | (22.0m) | (28.0m) | (35.0m) | 37.0m | 49.0m |
| USD | FY, 2017 |
|---|---|
EV/CFO | 28.6 x |
Revenue/Employee | 576.8k |
Debt/Equity | 2.8 x |
Debt/Assets | 0.6 x |
Financial Leverage | 4.8 x |
P/E Ratio | 41.0 |
Zoetis Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Performance Livestock Analytics | April 08, 2020 | |
| Ethos Diagnostic Science | February 07, 2020 | |
| Platinum Performance | July 22, 2019 | |
| Abaxis | May 15, 2018 | $1.90 b |
| Nexvet | April 03, 2017 | $85 m |
| Scandinavian Micro Biodevices | August 08, 2016 | $80 m |
| PHARMAQ | November 02, 2015 | $765 m |
| Bovigen | March 18, 2008 | |
| Abaxis Asia Holding Limited | ||
| Abaxis Europe GmbH |
Zoetis Revenue Breakdown
Zoetis revenue breakdown by business segment: 7.6% from Medicated Feed Additives, 12.4% from Dermatology, 12.6% from Other Pharmaceuticals, 15.6% from Parasiticides, 20.2% from Anti-infectives, 23.9% from Vaccines and 7.6% from Other
Zoetis revenue breakdown by geographic segment: 6.0% from Other Developed Markets, 12.0% from Other Emerging Markets, 51.9% from United States and 30.2% from Other
Zoetis Cybersecurity Score
Zoetis Environment, Social & Governance (ESG) Ratings
Zoetis Online and Social Media Presence
13.51k Twitter followers
Zoetis has 13.51k Twitter Followers. The number of followers has increased 0.1% month over month and increased 0.7% quarter over quarter
Zoetis's Trends
Twitter Engagement Stats for @Zoetis
1.9k
Tweets
364
Following
13.5k
Followers
6
Tweets last 30 days
5.2
Avg. likes per Tweet
83.3%
Tweets with engagement
Zoetis News and Updates
November 26, 2020
Europe Companion Animal Diagnostics Market Set to Expand by 2020-2027 Focusing on Key Players Zoetis Inc, Randox Laboratories, Ltd., Idexx Laboratories, Inc., IDvet, Virbac
The Europe companion animal diagnostics market is to reach US$ 792.8 million by 2027 from US$ 613.6 million in 2019. The market is anticipated to grow at a CAGR of 3.8% during 2019–2027. Posted via Industry Today. Follow us on Twitter @IndustryToday
November 11, 2020
Companion Animal Diagnostics Market examined in new market research report by top companies Skyla, Randox Laboratories, IDEXX Laboratories, Zoetis
The companion animal diagnostics marketwas valued at US$ 2,031.62 million in2019 and is projected to reach US$ 2,684.86 million by 2027; it is expected to grow at a CAGR of 4.1%from 2020to 2027. Posted via Industry Today. Follow us on Twitter @IndustryToday
August 13, 2020
Animal Prescription Drugs Market SWOT Analysis by Key Players- Elanco Animal Health, Zoetis, Virbac, Dechra
Stay up-to-date with Animal Prescription Drugs Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. Posted via Industry Today. Follow us on Twitter @IndustryToday
July 21, 2020
Consider Adding Zoetis, Garmin, And Intuit To Your Retirement Portfolio
Are you retiring? Or do you want to build a portfolio that offers steady returns with minimal risk? Then consider Zoetis, Garmin, Intuit, Roper Technologies, and Amphenol. When it comes to retirement, stability is the key. Thus, we identified these 5 companies that are worthy candidates for your...
July 15, 2020
$13.7 Billion Worldwide Animal Parasiticides Industry to 2025 - Featuring Merck, Zoetis & Virbac Among Others
DUBLIN, July 15, 2020 /PRNewswire/ -- The "Animal Parasiticides Market by Product (Ectoparasiticides, Endectocide (Ear Tags, Tablets, Dips, Injectables, Spot-on, Collars) Animal (Dogs, Cats, Cattle, Sheep, Goats, Horses) End-user (Veterinary Hospitals) - Global Forecast to 2025" report...
May 08, 2020
Zoetis Announces Pricing of $1.25 Billion of Senior Notes
Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.25
billion of senior notes, consisting of $750 million aggregate principal amount
of 2.000% senior notes due 2030 and $500 million aggregate principal amount of
3.000% senior notes due 2050, in an underwritten public offering.
Zoetis Frequently Asked Questions
When was Zoetis founded?
Zoetis was founded in 2012.
Who are Zoetis key executives?
Zoetis's key executives are Kristin Peck, Tim Bettington and Glenn David.
How many employees does Zoetis have?
Zoetis has 10,600 employees.
What is Zoetis revenue?
Latest Zoetis annual revenue is $6.3 b.
What is Zoetis revenue per employee?
Latest Zoetis revenue per employee is $590.6 k.
Who are Zoetis competitors?
Competitors of Zoetis include Elanco, IDEXX Laboratories and Bayer.
Where is Zoetis headquarters?
Zoetis headquarters is located at 10 Sylvan Way, Parsippany, Parsippany-Troy Hills.
Where are Zoetis offices?
Zoetis has offices in Parsippany-Troy Hills, DXS, Silverwater, Wien and in 46 other locations.
How many offices does Zoetis have?
Zoetis has 51 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies